| Description | Carglumic Acid (Ureidoglutaric acid) is an orphan drug used to treat hyperammonemia in patients with N-acetyl glutamate synthase absence. This rare hereditary disease results in elevated blood levels of ammonia, which can eventually cross the blood-brain barrier and lead to neurologic problems, coma, cerebral edema, and death. Carglumic acid was approved by the U.S. FDA on 18 March 2010. |
| Synonyms | Carbaglu, N-Carbamylglutamate, N-Carbamyl-L-glutamic acid, 氨甲酰谷氨酸, Carbamylglutamic acid, Carbamino-L-glutamic acid, Ureidoglutaric acid |
| molecular weight | 190.15 |
| Molecular formula | C6H10N2O5 |
| CAS | 1188-38-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 45 mg/mL (236.66 mM) |
| References | 1. Carglumic acid. Prescrire Int. 2008 Apr;17(94):50-1. |